Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • HCW Biologics' Cash & Equivalents rose 969.09% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 969.09%. This contributed to the annual value of $4.7 million for FY2024, which is 3002.62% up from last year.
  • As of Q3 2025, HCW Biologics' Cash & Equivalents stood at $1.1 million, which was up 969.09% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Cash & Equivalents peaked at $48.8 million during Q3 2021, and registered a low of $1.0 million during Q3 2024.
  • Over the past 5 years, HCW Biologics' median Cash & Equivalents value was $8.2 million (recorded in 2021), while the average stood at $17.8 million.
  • Per our database at Business Quant, HCW Biologics' Cash & Equivalents surged by 70587.25% in 2022 and then tumbled by 9267.47% in 2024.
  • HCW Biologics' Cash & Equivalents (Quarter) stood at $44.4 million in 2021, then plummeted by 34.27% to $29.2 million in 2022, then plummeted by 87.69% to $3.6 million in 2023, then surged by 30.03% to $4.7 million in 2024, then plummeted by 76.53% to $1.1 million in 2025.
  • Its Cash & Equivalents stands at $1.1 million for Q3 2025, versus $2.4 million for Q2 2025 and $1.1 million for Q1 2025.